BACKGROUND: The long-term prognostic role of functional limitations among women with breast cancer is poorly understood. METHODS: We studied a cohort of 2202 women with breast cancer at two sites in the United States, who provided complete information on body functions involving endurance, strength, muscular range of motion, and small muscle dexterity following initial adjuvant treatment. Associations of baseline functional limitations with survival were evaluated in delayed entry Cox proportional hazards models, with adjustment for baseline sociodemographic factors, body mass index, smoking, physical activity, comorbidity, tumor characteristics, and treatment. Difference in covariates between women with and without limitations was assessed with Pearson χ(2) and Student t tests. All statistical tests were two-sided. RESULTS: During the median follow-up of 9 years, 112 deaths were attributable to competing causes (5% of the cohort) and 157 were attributable to breast cancer causes (7% of the cohort). At least one functional limitation was present in 39% of study participants. Proportionately, more breast cancer patients with functional limitations after initial adjuvant treatment were older, less educated, and obese (P < .001). In multivariable models, functional limitations were associated with a statistically significantly increased risk of death from all causes (hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.03 to 1.92) and from competing causes (HR = 2.60, 95% CI = 1.69 to 3.98) but not from breast cancer (HR = 0.90, 95% CI = 0.64 to 1.26). The relationship between functional limitations and overall survival differed by tumor stage (among women with stage I and stage III breast cancer, HR = 2.02, 95% CI = 1.23 to 3.32 and HR = 0.74, 95% CI = 0.42 to 1.30, respectively). CONCLUSION: In this prospective cohort study, functional limitations following initial breast cancer treatment were associated with an important reduction in all-cause and competing-cause survival, irrespective of clinical, lifestyle, and sociodemographic factors.
BACKGROUND: The long-term prognostic role of functional limitations among women with breast cancer is poorly understood. METHODS: We studied a cohort of 2202 women with breast cancer at two sites in the United States, who provided complete information on body functions involving endurance, strength, muscular range of motion, and small muscle dexterity following initial adjuvant treatment. Associations of baseline functional limitations with survival were evaluated in delayed entry Cox proportional hazards models, with adjustment for baseline sociodemographic factors, body mass index, smoking, physical activity, comorbidity, tumor characteristics, and treatment. Difference in covariates between women with and without limitations was assessed with Pearson χ(2) and Student t tests. All statistical tests were two-sided. RESULTS: During the median follow-up of 9 years, 112 deaths were attributable to competing causes (5% of the cohort) and 157 were attributable to breast cancer causes (7% of the cohort). At least one functional limitation was present in 39% of study participants. Proportionately, more breast cancerpatients with functional limitations after initial adjuvant treatment were older, less educated, and obese (P < .001). In multivariable models, functional limitations were associated with a statistically significantly increased risk of death from all causes (hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.03 to 1.92) and from competing causes (HR = 2.60, 95% CI = 1.69 to 3.98) but not from breast cancer (HR = 0.90, 95% CI = 0.64 to 1.26). The relationship between functional limitations and overall survival differed by tumor stage (among women with stage I and stage III breast cancer, HR = 2.02, 95% CI = 1.23 to 3.32 and HR = 0.74, 95% CI = 0.42 to 1.30, respectively). CONCLUSION: In this prospective cohort study, functional limitations following initial breast cancer treatment were associated with an important reduction in all-cause and competing-cause survival, irrespective of clinical, lifestyle, and sociodemographic factors.
Authors: B E Ainsworth; W L Haskell; M C Whitt; M L Irwin; A M Swartz; S J Strath; W L O'Brien; D R Bassett; K H Schmitz; P O Emplaincourt; D R Jacobs; A S Leon Journal: Med Sci Sports Exerc Date: 2000-09 Impact factor: 5.411
Authors: L K Staten; D L Taren; W H Howell; M Tobar; E T Poehlman; A Hill; P M Reid; C Ritenbaugh Journal: Med Sci Sports Exerc Date: 2001-11 Impact factor: 5.411
Authors: Dejana Braithwaite; C Martin Tammemagi; Dan H Moore; Elissa M Ozanne; Robert A Hiatt; Jeff Belkora; Dee W West; William A Satariano; Michael Liebman; Laura Esserman Journal: Int J Cancer Date: 2009-03-01 Impact factor: 7.396
Authors: Candyce H Kroenke; Bernard Rosner; Wendy Y Chen; Ichiro Kawachi; Graham A Colditz; Michelle D Holmes Journal: J Clin Oncol Date: 2004-05-15 Impact factor: 44.544
Authors: Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2009-04-29 Impact factor: 44.544
Authors: Tina E Brinkley; Xiaoyan Leng; Michael E Miller; Dalane W Kitzman; Marco Pahor; Michael J Berry; Anthony P Marsh; Stephen B Kritchevsky; Barbara J Nicklas Journal: J Gerontol A Biol Sci Med Sci Date: 2009-02-04 Impact factor: 6.053
Authors: Rachel Meadows; Timethia Bonner; Megha Dobhal; Sujana Borra; Jordan A Killion; Raheem Paxton Journal: Support Care Cancer Date: 2016-10-05 Impact factor: 3.603
Authors: Blas A Guigni; Dennis K Fix; Joseph J Bivona; Bradley M Palmer; James A Carson; Michael J Toth Journal: Am J Physiol Cell Physiol Date: 2019-09-18 Impact factor: 4.249
Authors: Catherine M Alfano; Deborah K Mayer; Smita Bhatia; Jane Maher; Jessica M Scott; Larissa Nekhlyudov; Janette K Merrill; Tara O Henderson Journal: CA Cancer J Clin Date: 2019-03-08 Impact factor: 508.702
Authors: Arti Hurria; Enrique Soto-Perez-de-Celis; Jacob B Allred; Harvey Jay Cohen; Anait Arsenyan; Karla Ballman; Jennifer Le-Rademacher; Aminah Jatoi; Julie Filo; Jeanne Mandelblatt; Jacqueline M Lafky; Gretchen Kimmick; Heidi D Klepin; Rachel A Freedman; Harold Burstein; Julie Gralow; Antonio C Wolff; Gustav Magrinat; Myra Barginear; Hyman Muss Journal: J Am Geriatr Soc Date: 2018-08-26 Impact factor: 5.562
Authors: Catherine Marinac; Ruth E Patterson; Adriana Villasenor; Shirley W Flatt; John P Pierce Journal: J Cancer Surviv Date: 2014-02-26 Impact factor: 4.442
Authors: Marloes G M Derks; Nienke A de Glas; Esther Bastiaannet; Anton J M de Craen; Johanneke E A Portielje; Cornelis J H van de Velde; Floor E van Leeuwen; Gerrit-Jan Liefers Journal: Oncologist Date: 2016-07-01
Authors: Mackenzi Pergolotti; Allison M Deal; Grant R Williams; Ashley L Bryant; Jeannette T Bensen; Hyman B Muss; Bryce B Reeve Journal: J Geriatr Oncol Date: 2017-03-09 Impact factor: 3.599